Myricx Bio

Biotech · Private

NMT inhibitor antibody-drug conjugate (ADC) platform targeting N-myristoyltransferase lipid modification

myricxbio.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2321Genomics PLC——
2322Lennham Pharmaceuticals, Inc.—$3.5M
2323SUS CLINICALS INC—$3.5M
2324Myricx Bio——
2325Abiologics——
2326APT THERAPEUTICS, INC.——
2327Landos Biopharma—$60M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.